Ap53genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers

Authors

  • Ming-Whei Yu,

    1. School of Public Health Chang-Gung University, Taipei, Taiwan
    2. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan; Chang-Gung University, Taipei, Taiwan
    Search for more papers by this author
  • Shi-Yi Yang,

    1. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan; Chang-Gung University, Taipei, Taiwan
    Search for more papers by this author
  • Yueh-Hsia Chiu,

    1. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan; Chang-Gung University, Taipei, Taiwan
    Search for more papers by this author
  • Yi-Ching Chiang,

    1. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan; Chang-Gung University, Taipei, Taiwan
    Search for more papers by this author
  • Yun-Fan Liaw,

    1. Liver Research Unit, Chang-Gung Memorial Hospital, Chang-Gung University, Taipei, Taiwan
    Search for more papers by this author
  • Chien-Jen Chen

    Corresponding author
    1. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan; Chang-Gung University, Taipei, Taiwan
    • Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, No. 1 Jen-Ai Road Section 1, Room 1547, Taipei 100, Taiwan. fax: 886-2-23511955
    Search for more papers by this author

Abstract

This study evaluated whether the codon 72 p53 polymorphism was related to hepatocellular carcinoma (HCC). Genotypes of p53were determined in 80 incident cases of HCC and 328 controls nested in a cohort study of 4,841 male chronic hepatitis B carriers. No overall increase in HCC risk with thePro variant allele of thep53 polymorphism was apparent. However, there were synergistic effects on HCC development for the Pro allele with chronic liver disease and family history of HCC in first-degree relatives. Compared with subjects without the Pro allele and chronic liver disease, the increase in HCC risk associated with chronic liver disease among those without the Pro allele was only threefold. Subjects with both chronic liver disease and the Pro allele were at an increased risk of 7.60 (95% CI = 2.28-25.31). When subjects without family history of HCC and the Pro allele were considered as the reference group, there was no apparent increased risk of HCC for those without thePro allele who had family history of HCC. Among those with both factors, there was a significantly increased risk of 3.29 (95% CI = 1.10-9.85). Both cigarette smoking and glutathioneS-transferase M1 genotype modified the risk of HCC associated with the p53polymorphism. Significantly increased risk associated with the p53genotype was observed only among smokers who were glutathione S-transferase–null (Pro/Pro vs. Arg/Arg: odds ratio = 6.46; 95% CI = 1.55-26.94). The p53polymorphism also interacted with the cytochrome P4501A1and carotenoid levels in smoking-related hepatocarcinogenesis.

Ancillary